🔗 Share this article

While America proceeds with historic revisions to its vaccine guidelines, one figure has emerged somewhat surprisingly: Høeg, a US-based sports medicine doctor and public health researcher who rose to prominence by casting doubt on COVID-19 vaccinations during the global health crisis and has zeroed in on potential deaths following Covid vaccination in her short time at the FDA.

Proposed Changes to Pediatric Vaccine Schedule

Health officials had intended to unveil major changes to the pediatric vaccination calendar earlier this month, synchronizing the US with Denmark’s national calendar, it is understood – a significant shift that would put the US at odds with many the international standard with no evidence for public health gain. This reveal has been pushed back until the new year.

In place of the director of the vaccine center, Tracy Beth Høeg is scheduled to speak at the event. She was recently named temporary leader of the FDA’s drug evaluation center, the fifth appointee to head the center this year.

Consolidating Power at the FDA

Høeg's temporary position may indicate a strengthened alliance between the drug and biologics centers as Dr. Høeg and Prasad consolidate power at the FDA – and it points to a increased emphasis upon reevaluating long-standing vaccines at the FDA.

Dr. Høeg has frequently advocated for ending specific childhood shot schedules in the US to become more similar to the Danish model, a country with comprehensive healthcare and a citizenry approximately the size of the state of Wisconsin.

So far statements, she has continued to focus on vaccines – typically the responsibility of Dr. Prasad, chief of the FDA’s Center for Biologics Evaluation and Research (CBER) – as opposed to pharmaceutical oversight.

Doubts Over Qualifications

Dr. Høeg has little discernible experience in pharmaceutical research, oversight or leadership, which has been customary for previous leaders of the Center for Biologics Evaluation and Research. She has served at the FDA as a senior adviser to the commissioner and CBER since earlier this year.

“It seems she lacks to have the necessary background” for overseeing the pharmaceutical oversight division, stated Dr. Jonathan Howard. “She lacks experience running a scientific study. She is not versed in running a major agency. She lacks background in pharmaceutical oversight.”

Past commissioners of CBER would “understand laws and regulations and the research of pharmaceutical innovation”, commented Janet Woodcock. “Frankly, she lacks the type of experience that former directors who led CBER have had.”

CDER has an enormous portfolio at the agency, the former commissioner pointed out.

“Many people just pays attention on the new drug program, but the off-patent medication office approves numerous generic medications. There is also a biologic copycat branch, OTC medication office and so forth, and every single one must be looked after,” she said. “The responsibility you overlook, that is precisely what that I always told people is going to cause problems.”

There is also, a significant management component to the role, which supervises over 5,000 staff members. “It’s a huge leadership role, if you execute it properly,” the former official added.

Agency Reaction and Contentious Policies

When asked about questions about Høeg’s qualifications and whether this assignment indicates greater collaboration among agency officials on vaccines, a representative responded that the “inquiries stem from inaccurate assumptions”.

“Her experience aligns with the responsibilities of her job,” the official stated, citing the period Høeg spent guiding the FDA commissioner on “pharmaceutical safety and oversight research, including computational safety modeling and shot safety tracking”.

As the temporary head, Høeg assumes responsibility for the commissioner’s controversial expedited review system, a controversial rapid therapy clearance system that reportedly worried her predecessors. “By what process are these medications being chosen for this fast-track system? Who is making the choices?” Howard asked. “There is a lot of lack of transparency occurring at the FDA right now.”

Broadly speaking, he stated, “the Food and Drug Administration appears to be shifting towards more relaxed rules of pharmaceuticals, with the exception of shots.”

Public Track Record on Vaccines

With vaccines, Høeg has a clearer, if troubling, past, Howard have noted. She released a study using unverified crowd-sourced reports to assess the incidence of myocarditis after Covid immunization. She consulted for the Florida top health official Dr. Joseph Ladapo, who reportedly have changed statistics to imply Covid vaccinations are pose a greater threat than they are.

Included in her “desired changes” for the incoming administration featured changing regulations for new vaccines and halting “unnecessary” vaccines, she stated post-election on a audio program. At the FDA, Dr. Høeg has allegedly proposed preventing teenage boys from getting Covid vaccines.

“She is an thorough ideologue who begins with her preconceived notions and works backwards to retrofit the science in a very deceptive, fraudulent fashion,” Howard said.

Gaining Influence and a “Push for Payback”

Høeg aligned with other skeptics, {like|